Archives: Agenda
CASE STUDY: Real-Life AI in Clinical Supply Chain: What’s Working Right Now for EIKON 📊 LIVE POLL
- How Eikon is deploying AI today across vendor oversight, demand planning, compliance documentation and stakeholder communication
- Separating Real-World Value from the Hype: Discover what worked, what failed, and what the team would do differently, gaining a grounded perspective on where AI delivers genuine ROI versus where it falls short
- Learn how practical AI tools are uncovering hidden logistics risks and driving operational efficiencies in ways traditional supply chain software simply cannot match
Speaking Slot Available
Session reserved for Technology showcase
Strategies for Preserving Valuable Biomarkers in Blood
- Addressing logistical challenges in clinical trials for blood sample processing.
- Implementing solutions to stabilize biomarkers at collection and simplify workflows.
Session reserved for Technology showcase
Reserved for TFS HealthScience
Choosing The Right CRO: Key Considerations for Small Biotech’s
- Evaluating CRO capabilities and experience relevant to your specific therapeutic area and development stage
- Balancing cost, quality and timelines within tight budget constraints
- Negotiating contracts with flexibility to protect your biotech’s goals
Biotechs and FDA’s “Real-Time Clinical Trials” program: Postpone the myth or prepare for reality?
This session will explore whether the FDA’s Real-Time Clinical Trials (RTCT) program is an aspirational vision for the future or a near-term reality that biotech companies should begin preparing for today. This session will discuss what sponsors can do now to position themselves for participation in this emerging real-time development model.
- Separate hype from reality: Examine FDA’s stated goals for RTCTs, the scope of the pilot program, and its potential opportunities and limitations.
- Understand the broad operational and technology requirements: Identify the critical capabilities needed for participation in the pilot program.
- Develop your biotech readiness roadmap: Discuss practical actions sponsors can take today to assess their organizational readiness and engage with FDA as the RTCT model evolves.
When “Real Time” Is Already Too Late: Lessons from Biomarker Operations
- What “real time” looked like from the sponsor side when site activity became visible only after the work was complete
- How late queries and accessioning delays slowed data readout in a Phase I oncology study
- What changed when issues were identified and corrected before shipment
- Why clinical trial execution is foundational to better data and AI-ready trials